A Study of Barzolvolimab in Patients With Prurigo Nodularis
← catalyst calendarSponsored by Celldex Therapeutics (industry) · CLDX — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
140actual
Sites
72
Countries
Canada, Croatia, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-12 | actual | When the study began enrolling |
| Primary completion | 2026-03-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prurigo Nodularis
Interventions
- Biological: barzolvolimab
- Other: Matching Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants with improvement in Worst Itch Numeric Rating Scale (WI-NRS) by ≥ 4 from baseline to Week 12.
measured From Day 1 (first dose) to Day 85 (week 12)
Permalink · CLDX's whole pipeline · Catalyst calendar · Every registered study · What changed